CytomX Therapeutics, Inc. (CTMX)
Market Cap | 178.43M |
Revenue (ttm) | 71.94M |
Net Income (ttm) | -97.59M |
Shares Out | 66.08M |
EPS (ttm) | -1.49 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 924,723 |
Open | 2.63 |
Previous Close | 2.68 |
Day's Range | 2.63 - 2.74 |
52-Week Range | 1.17 - 4.73 |
Beta | 0.40 |
Analysts | Hold |
Price Target | 2.88 (+6.67%) |
Earnings Date | Feb 27, 2023 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gas... [Read more]
Financial Performance
In 2021, CTMX's revenue was $69.57 million, a decrease of -30.68% compared to the previous year's $100.36 million. Losses were -$83.61 million, 154.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for CTMX stock is "Hold." The 12-month stock price forecast is $2.88, which is an increase of 6.67% from the latest price.
News

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX-

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal
On a resoundingly positive Friday for the market, CytomX Therapeutics (NASDAQ: CTMX) is providing a large portion of the fireworks. Specifically, CTMX stock skyrocketed more than 50% before settling ...

CytomX shares surge more than 50% on Moderna partnership
CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares ...

Moderna signs $35 million deal with cancer drug developer CytomX
Moderna Inc on Thursday announced a $35 million licensing deal with cancer-focused drug developer CytomX Therapeutics to work on messenger RNA-based therapies for a wide range of diseases.

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront...

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to dete...

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it...

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Se...

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that P...

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
CytomX Therapeutics (NASDAQ: CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN). This strategic partnership will see the two compa...

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody ® and Regeneron's Veloci-Bi ® platforms -

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody® and Regeneron's Veloci-Bi ® platforms CytomX to receive $30 million upfr...

CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 -

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -

CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Se...

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it...

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb -- BMS-986249 Phase 2 study ongoing -

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
- Presentation at World ADC Conference in San Diego -

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 -